US EditionPublished • loading... • Updated
Xanax Bottles Recalled Nationwide over Dissolution Issues
The voluntary recall covers 1 lot of 3 mg extended-release tablets after the FDA said the pills failed dissolution tests.
- Viatris Inc. initiated a nationwide recall for lot #8177156 of 3mg Xanax XR extended-release tablets, removing the product from circulation following identification of quality control defects.
- According to the Food and Drug Administration, the drug was recalled because it "failed dissolution specifications," a defect health officials noted could mean the pills are less effective or fail to release the correct dosage.
- Distributed nationwide between August 27, 2024, and May 29, 2025, the affected bottles carry an expiration date of February 28, 2027, according to the California State Board of Pharmacy.
- The FDA designated this as a Class II recall, which means "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences."
- Xanax is primarily used to treat anxiety and panic disorders as a benzodiazepine that enhances neurotransmitter activity; Viatris did not immediately respond to requests for comment regarding the recall initiated last month.
Insights by Ground AI
54 Articles
54 Articles
Anxiety drug Xanax recalled nationwide: How to check if your prescription is included
Bottles of Xanax – one of the most widely-prescribed medications for anxiety – have been recalled after failing a quality-control test, according to the Food and Drug Administration.
·New York, United States
Read Full Article
KTAL NBC 6 NewsReposted by 
KTSM
KTSMXanax XR recalled over quality concerns,FDA warns patients
The U.S. Food and Drug Administration has issued a Class II recall of one lot of Xanax XR (alprazolam) extended-release tablets due to potential quality concerns that could affect how the drug works in patients.
Coverage Details
Total News Sources54
Leaning Left4Leaning Right1Center37Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
Factuality
To view factuality data please Upgrade to Premium
